• Explore /
  • Poster
  • / Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.

Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.

Abstract Poster

Authors

null

Ray Comenzo

Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

Ray Comenzo , Efstathios Kastritis , Mathew Maurer , Jeffrey A. Zonder , Monique Minnema , Stefan Schönland , Ashutosh Wechalekar , Giovanni Palladini , Xiang Qin , Sandra Y. Vasey , Imran Khan , Jordan Mark Schecter , Giampaolo Merlini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Plasma Cell Disorders

Clinical Trial Registration Number

NCT03201965

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8011)

DOI

10.1200/JCO.2018.36.15_suppl.8011

Abstract #

8011

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Robert M. Rifkin

First Author: Saad Z. Usmani

First Author: Nizar J. Bahlis

First Author: E. Bridget Kim